SERUM IMMUNOGLOBULIN LEVEL FOLLOWING THE TREATMENT IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA
Keywords:
acute lymphoblastic leukemia, secondary immunodeficiency, immunoglobulin therapyAbstract
Introduction: Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, requiring intensive chemotherapy that can lead to immune suppression and secondary immunodeficiency. This study evaluates serum immunoglobulin (Ig) levels before and after intensive therapy in children with ALL.
Methods: Serum levels of IgA, IgG, and IgM were analyzed in children with ALL before chemotherapy initiation and after completing intensive treatment. Results were compared with a healthy control group. Statistical analysis was performed using the t-test, with significance set at p < 0.05.
Results: Before treatment, Ig levels in children with ALL did not differ significantly from those in the healthy control group (p > 0.05). However, after intensive therapy, IgA, IgG, and IgM levels showed a significant decline (p < 0.05). The decrease was more pronounced in children aged 6 to 12 years.
Conclusion: Intensive chemotherapy leads to a significant reduction in serum immunoglobulin levels, increasing the risk of infections. The results highlight the need for further research on intravenous immunoglobulin (IVIG) supplementation as a potential strategy to improve immune function in pediatric ALL patients undergoing treatment
References
Malard F, Mohty M. Acute lymphoblastic leukemia. Lancet 2020; 395(10230): 1146-1162. doi: 10.1016/S0140-6736(19)33018-1.
Steliarova-Foucher E, Colombet M, Ries LAG, Moreno F, Dolya A, Bray F, et al. International incidence of childhood cancer, 2001-10: a population-based registry study. Lancet Oncol 2017; 18(6): 719-731. doi: 10.1016/S1470-2045(17)30186-9.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019; 69(1): 7-34. doi: 10.3322/caac.21551.
Schrappe M, Reiter A, Zimmermann M, Harbott J, Ludwig WD, Henze G, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster. Leukemia 2000; 14(12): 2205-2222. doi: 10.1038/sj.leu.2401973.
Schrappe M, Reiter A, Riehm H. Cytoreduction and prognosis in childhood acute lymphoblastic leukemia. J Clin Oncol 1996; 14(8): 2403-2406. doi: 10.1200/JCO.1996.14.8.2403.
A Reiter, M Schrappe, W D Ludwig, W Hiddemann, S Sauter, G Henze, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86, Blood. 1994 Nov 1;84(9):3122-33.
Schrappe M, Reiter A, Ludwig WD, Harbott J, Zimmermann M, Hiddemann W, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood 2000; 95(11): 3310-3322. PMID: 10828010.
Smith S, Schiffman G, Karayalcin G, Bonagura V. Immunodeficiency in long-term survivors of acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster therapy. J Pediatr 1995; 127(1): 68-75. doi: 10.1016/s0022-3476(95)70259-8.
Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol 2012; 30(14): 1663-1669. doi: 10.1200/JCO.2011.37.8018.
Raje N, Snyder BL, Hill DA, Streicher JL, Sullivan KE. Severe immunodeficiency associated with acute lymphoblastic leukemia and its treatment. Ann Allergy Asthma Immunol 2018; 120(5): 537-538.e1. doi: 10.1016/j.anai.2017.12.023.
Osman Yokus, Konul Jafarli, Fettah Sametoglu, Hasan Goze, Istemi Serin, Secondary Immunodeficiency Frequency in Patients with Chronic Lymphocytic Leukemia: The Relationship with Stage and Treatment, Int J Hematol Oncol Stem Cell Res. 2022 Jan 1;16(1):14–21. doi: 10.18502/ijhoscr.v16i1.8437
C da Cunha-Bang, J Simonsen, K Rostgaard, C Geisler, H Hjalgrim, C U Niemann, Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo-immunotherapy: a Danish population-based study of 10455 patients, Blood Cancer J. 2016 Nov 11;6(11):e499.doi: 10.1038/bcj.2016.105.
Omar Benbrahim, Jean-François Viallard, Sylvain Choquet, et al. The use of octagam and gammanorm in immunodeficiency associated with hematological malignancies: a prospective study from 21 French hematology departments, Hematology. 2019 Dec;24(1):173-182. doi: 10.1080/10245332.2018.1538001.
Benjamin W Teh, Simon J Harrison, Leon J Worth, Tim Spelman, Karin A Thursky, Monica A Slavin, Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy, Br J Haematol. 2015 Oct;171(1):100-8.doi: 10.1111/bjh.13532. Epub 2015 Jun 24.
Marcie Tomblyn, Tom Chiller, Hermann Einsele, Ronald Gress, Kent Sepkowitz, Jan Storek, John R Wingard, Jo-Anne H Young, Michael J Boeckh; Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009 Oct;15(10):1143-238. doi: 10.1016/j.bbmt.2009.06.019.
El-Chennawi FA, Al-Tonbary YA, Mossad YM, Ahmed MA. Immune reconstitution during maintenance therapy in children with acute lymphoblastic leukemia, relation to co-existing infection. Hematology 2008; 13(4): 203-209. doi:
1179/102453308X316086.
Patel SY, Carbone J, Jolles S. The Expanding Field of Secondary Antibody Deficiency: Causes, Diagnosis, and Management. Front Immunol 2019; 10: 33. doi: 10.3389/fimmu.2019.00033.
Afzal S, Ethier MC, Dupuis LL, Tang L, Punnett AS, Richardson SE, et al. Risk factors for infection-related outcomes during induction therapy for childhood acute lymphoblastic leukemia. Pediatr Infect Dis J 2009; 28(12): 1064-1068. doi: 10.1097/INF.0b013e3181aa6eae.
O'Connor D, Bate J, Wade R, ClackR, Dhir S, Hough R, et al. Infection-related mortality in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003. Blood 2014; 124(7): 1056-1061. doi: 10.1182/blood-2014-03-560847.
Kosmidis S, Baka M, Bouhoutsou D, Doganis D, Kallergi C, Douladiris N, et al. Longitudinal assessment of immunological status and rate of immune recovery following treatment in children with ALL. Pediatr Blood Cancer. 2008; 50(3): 528-532. doi: 10.1002/pbc.21327.
Łuczyński W, Stasiak-Barmuta A, Krawczuk-Rybak M, Kasprzycka E, Zak J, Nowakowska M.Is cellular immunity not impaired after remission induction in acute lymphoblastic leukemia in children. Pol Merkur Lekarski. 2004;16(91):17-21. Polish. PMID: 15080084.
Cheng FW, Leung TF, Chan PK, Leung WK, Lee V, Shing MK, et al. Recovery of humoral and cellular immunities to vaccine-preventable infectious diseases in pediatric oncology patients. Pediatr Hematol Oncol 2010; 27(3): 195-204. doi: 10.3109/08880011003621752.
Mustafa MM, Buchanan GR, Winick NJ, McCracken GH, Tkaczewski I, Lipscomb M, et al. Immune recovery in children with malignancy after cessation of chemotherapy. J Pediatr Hematol Oncol 1998; 20(5): 451-457. doi: 10.1097/00043426-199809000-00008.
Stephen Jolles, Mauricette Michallet, Carlo Agostini, Michael H Albert, David Edgar, Roberto Ria, Livio Trentin, Vincent Lévy, Treating secondary antibody deficiency in patients with hematological malignancy: European expert consensus, Eur J Haematol. 2021 Apr;106(4):439-449. doi: 10.1111/ejh.13580.
Reiser M, Borte M, Huscher D, Baumann U, Pittrow D, Sommer C, et al. Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: Long-term data of the SIGNS study. Eur J Haematol 2017; 99(2): 169-177. doi: 10.1111/ejh.12900.
Martín Ibáñez I, Arce Casas A, Cruz Martínez O, Estella Aguado J, Martín Mateos MA. Humoral immunity in pediatric patients with acute lymphoblastic leukaemia. Allergol Immunopathol (Madr) 2003; 31(6): 303-310. doi: 10.1016/s0301-0546(03)79203-9.
İnce T, Tüfekçi Gürocak Ö, Totur G, Yılmaz Ş, Ören H, Aydın A. Waning of Humoral Immunity to Vaccine-Preventable Diseases in Children Treated for Acute Lymphoblastic Leukemia: A Single-Center Retrospective Cross-Sectional Analysis. Turk J Haematol 2024; 41(3): 160-166. doi: 10.4274/tjh.galenos.2024.2024.0150.
Committee for Medicinal Products for Human Use (CHMP), Guideline on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIg) December 2021, EMA/CHMP/BPWP/94033/2007 rev. 4
Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet 2013; 381(9881): 1943-55. doi: 10.1016/S0140-6736(12)62187-4.
Gaynon PS, Trigg ME, Heerema NA, Sensel MG, Sather HN, Hammond GD, et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia. 2000 dec; 14(12): 2223-2233. doi: 10.1038/sj.leu.2401939.
Cinetto F, Neri R, Vianello F, Visentin A, Barilà G, Gianese S, et al. Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: Real life evidence as compared to primary antibody deficiencies. PLoS One 2021; 16(3): e0247717. doi: 10.1371/journal.pone.0247717.
Borte M, Baumann U, Pittrow D, Hensel M, Fasshauer M, Huscher D, et al. Liste der aktuell beitragenden Zentren, sortiert nach Postleitzahlen (mindestens ein Patient zum 1.3.2012). Anwendung von Immunglobulinen bei primären und sekundären Immundefekten und neurologischen Autoimmunerkrankungen [Immunoglobulins in PID, SID and neurological autoimmune disease]. Dtsch Med Wochenschr 2012; 137(13): 675-680. German. doi: 10.1055/s-0032-1304844.
